PTHS Stock Forecast: Pelthos Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.38
−8.73% on the day

The median 12-month analyst price target for Pelthos Therapeutics, Inc. is $40. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$25.1M
Ticker Nerd rank
37/ 100
Median analyst target
$40
Analysts covering
7
Revenue$15.6M
Operating income−$17.3M
Net income−$23.4M
Free cash flow−$7.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.2%
1M
−68.9%
YTD
−79.4%
1Y
−78.0%
From 52W high
−79.4%
From 52W low
0.0%
$6
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pelthos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
37/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
69
Value
67
Quality
55
Revisions
52
Volatility
37
Momentum
29
Growth
10
Issuance
3

Accruals (69): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PTHS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTHS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26PTHSHigh $60Median $40Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6
Buy
1
Hold
0
Sell
$21
Low
$40
Median
$60
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026Lake StreetMaintainsBuy—
14 Aug 2026OppenheimerMaintainsOutperform—
15 May 2026OppenheimerMaintainsOutperform—
1 Apr 2026Cantor FitzgeraldInitiatesOverweight—
20 Mar 2026OppenheimerMaintainsOutperform—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Feb 2026Piper SandlerInitiatesOverweight—
26 Feb 2026Roth CapitalMaintainsBuy—
26 Jan 2026OppenheimerMaintainsOutperform—
3 Dec 2025HC Wainwright & Co.InitiatesBuy—
3 Dec 2025Lake StreetInitiatesBuy—
25 Nov 2025Roth CapitalInitiatesBuy—
14 Nov 2025OppenheimerReiteratesOutperform—
2 Sept 2025OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PTHS.

Market Radar

This page is one stock. Monday covers all of them.

PTHS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PTHS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pelthos Therapeutics, Inc. returned −78.0% against +6.9% for the S&P 500, dividends included.

PTHS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PTHSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTHS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.5×

Cheaper than 79% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
107.9%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
17.8%

Higher than 18% of US stocks

Operating margin
−98.7%

Higher than 14% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−24.8%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pelthos Therapeutics, Inc. has a market value of $25.1M and an enterprise value of $75.7M.

  • Revenue in the twelve months to 30 June 2026: $43.3M.

  • Net income over the same four quarters: −$86.4M, a −199.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$21.88.

  • Free cash flow in the twelve months to 30 June 2026: −$50.5M.

  • Shares outstanding: 3.7M.

  • Pelthos Therapeutics, Inc. employs 92 people — $471K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PTHS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTHSPelthos Therapeutics, Inc.$25.1M37
LITSLite Strategy, Inc.$24.4M33
INMBINmune Bio, Inc.$25.6M38
ABVCABVC BioPharma, Inc.$23.1M20
LONALeonaBio, Inc.$26.4M25
EYPTEyePoint, Inc.$26.6M21
TELOTelomir Pharmaceuticals, Inc.$26.8M27

Take a look at PTHS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pelthos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PTHS

What is the PTHS stock price forecast for 2026-2027?

The median 12-month analyst price target for Pelthos Therapeutics, Inc. is $40, with estimates ranging from $21 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTHS stock a buy right now?

Of the 7 analysts covering Pelthos Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pelthos Therapeutics, Inc. 37 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTHS?

As at 21 Nov 2026, Pelthos Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (69 of 100).

Will PTHS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $40, and Ticker Nerd's factor model ranks Pelthos Therapeutics, Inc. 37 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTHS stock forecast for 2030?

No analyst covering Pelthos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTHS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $60 over the next 12 months.

How has PTHS stock performed over the past year?

Pelthos Therapeutics, Inc. returned -78.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pelthos Therapeutics, Inc. do?

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The company’s current portfolio centers on dermatology and cutaneous infectious diseases, led by ZELSUVMI® (berdazimer) topical gel for molluscum contagiosum, a prescription treatment designed for use at home by patients, parents, and caregivers.

Company

About Pelthos Therapeutics, Inc.

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The company’s current portfolio centers on dermatology and cutaneous infectious diseases, led by ZELSUVMI® (berdazimer) topical gel for molluscum contagiosum, a prescription treatment designed for use at home by patients, parents, and caregivers. Pelthos Therapeutics also markets XEPI® (ozenoxacin) Cream for impetigo and XEGLYZE® (abametapir) for head lice, giving it a commercial presence across several topical treatments used in everyday outpatient care. In addition, the company works with a proprietary nitric oxide-based technology platform, Nitricil, which supports its product development and commercialization efforts. Based in Durham, North Carolina, Pelthos Therapeutics operates as a commercial-stage specialty biotech company serving dermatology and infectious disease markets.

CEO Mr. Scott M. Plesha · 92 employees · United States · https://pelthos.com